FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017597613> ?p ?o ?g. }

• W2017597613 endingPage "107" @default.
• W2017597613 startingPage "103" @default.
• W2017597613 abstract "Little data are available on antibiotic (AB) use in French hospitals. 1995–2001 annual data on WHO defined daily doses (DDD) and hospitalization days (HD) were collected from volunteer hospitals. Twenty-three AB (amikacin, aztreonam, cefepime, cefotaxime, cefpirome, ceftazidime, ceftriaxone, ciprofloxacin, fosfomycin, fusidic acid, levofloxacin, imipenem, isepamicin, ofloxacin, pefloxacin, piperacillin, piperacillin/tazobactam, quinupristin/dalfopristin, sulbactam, teicoplanin, ticarcillin, ticarcillin-clavulanic acid, vancomycin) and four antifungals (amphotericin B lipid formulations, caspofungin, and fluconazole) were surveyed. Antimicrobial use was expressed as the number of DDD per 1000 HD. Fifty-eight hospitals participated in the 2001 study. AB consumption was higher in hospitals with > 400 acute care beds (214.8 ± 116 DDD/HD) than in 200–400 beds hospitals (134.2 ± 39 DDD/HD) or < 200 beds hospitals (104.3 ± 74 DDD/HD) P = 0.0005. Wide variations in AB choice and volumes were observed among similar sized hospital. Fifteen hospitals, representing one third of the region's acute care beds, provided complete 7-year data. The use of antibacterials increased 23% from 119.9 to 147.2 DDD per 1000 HD. Most of this increase was due to fluoroquinolones (plus 72%; 17.8 vs. 30.6, P = 0.0068), ceftriaxone (plus 90%; 14.4 vs. 27.4; P < 0.0001), and cefepime (plus 264%; 3.4 vs. 12.2%, P = 0.028). The only decreasing class was aminoglycosides (minus 48%; 27.7 vs. 14.5; P = 0.003). This data confirms the high level of AB consumption in French hospitals. Il y a peu de données sur la consommation hospitalière des antibiotiques en France. Nous avons collecté de 1995 à 2001 la consommation en doses définies journalières (DDJ) et les journées d'hospitalisation (JH) d'hôpitaux volontaires. La surveillance a porté sur : 23 antibiotiques (amikacine, aztréonam, céfépime, céfotaxime, cefpirome, ceftazidime, ceftriaxone, ciprofloxacine, fosfomycine, acide fusidique, lévofloxacine, imipéneme, isépamicine, ofloxacine, pefloxacine, pipéracilline (± tazobactam, quinupristine/dalfopristine, sulbactam, teicoplanine, ticarcillin ± acide clavulanique, vancomycine) et quatre antifungiques (amphotéricine B lipidiques, caspofungine, fluconazole). Les données sont exprimées en DDJ/1000 JH. Cinquante-huit hôpitaux ont participé en 2001. La consommation était plus élevée dans les hôpitaux de plus de > 400 lits de MCO (214,8 ± 116 DDJ/JH) que dans ceux entre 200 et 400 (134,2 ± 39 DDJ/JH) ou de moins de 200 (104,3 ± 74 DDJ/JH) p = 0,0005. Des variations importantes étaient notées chez des hôpitaux de taille similaire. Quinze hôpitaux, représentant 1/3 des lits de MCO de la région ont fourni des données pendant sept ans. La consommation a augmenté de 23 % (119,9 à 147,2 DDJ/JH). L'essentiel de l'augmentation portait sur les fluoroquinolones (plus 72 %; 17,8 vs 30,6, p = 0,0068), la ceftriaxone (plus 90 %; 14,4 vs 27,4; p < 0,0001) et le céfépime (plus 264 %; 3,4 vs. 12,2 %, p = 0,028). La seule classe en diminution était les aminosides (moins 48 %; 27,7 vs. 14,5; p = 0,003). Cela confirme le niveau élevé de consommation antibiotique dans les hôpitaux français." @default.
• W2017597613 created "2016-06-24" @default.
• W2017597613 creator A5017789185 @default.
• W2017597613 creator A5035871622 @default.
• W2017597613 creator A5054101981 @default.
• W2017597613 creator A5077135153 @default.
• W2017597613 date "2007-02-01" @default.
• W2017597613 modified "2023-10-01" @default.
• W2017597613 title "Use of 27 parenteral antimicrobial agents in north of France hospitals" @default.
• W2017597613 cites W1538455569 @default.
• W2017597613 cites W2022014720 @default.
• W2017597613 cites W2156657551 @default.
• W2017597613 cites W2171609823 @default.
• W2017597613 cites W2182049775 @default.
• W2017597613 cites W32045345 @default.
• W2017597613 doi "https://doi.org/10.1016/j.medmal.2006.10.010" @default.
• W2017597613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17303361" @default.
• W2017597613 hasPublicationYear "2007" @default.
• W2017597613 type Work @default.
• W2017597613 sameAs 2017597613 @default.
• W2017597613 citedByCount "16" @default.
• W2017597613 countsByYear W20175976132012 @default.
• W2017597613 countsByYear W20175976132014 @default.
• W2017597613 countsByYear W20175976132015 @default.
• W2017597613 countsByYear W20175976132016 @default.
• W2017597613 countsByYear W20175976132017 @default.
• W2017597613 crossrefType "journal-article" @default.
• W2017597613 hasAuthorship W2017597613A5017789185 @default.
• W2017597613 hasAuthorship W2017597613A5035871622 @default.
• W2017597613 hasAuthorship W2017597613A5054101981 @default.
• W2017597613 hasAuthorship W2017597613A5077135153 @default.
• W2017597613 hasConcept C126322002 @default.
• W2017597613 hasConcept C2776083883 @default.
• W2017597613 hasConcept C2777050379 @default.
• W2017597613 hasConcept C2777457247 @default.
• W2017597613 hasConcept C2777637488 @default.
• W2017597613 hasConcept C2778193466 @default.
• W2017597613 hasConcept C2778266534 @default.
• W2017597613 hasConcept C2778897966 @default.
• W2017597613 hasConcept C2779631663 @default.
• W2017597613 hasConcept C4937899 @default.
• W2017597613 hasConcept C501593827 @default.
• W2017597613 hasConcept C523546767 @default.
• W2017597613 hasConcept C54355233 @default.
• W2017597613 hasConcept C71924100 @default.
• W2017597613 hasConcept C86803240 @default.
• W2017597613 hasConcept C89423630 @default.
• W2017597613 hasConcept C94665300 @default.
• W2017597613 hasConceptScore W2017597613C126322002 @default.
• W2017597613 hasConceptScore W2017597613C2776083883 @default.
• W2017597613 hasConceptScore W2017597613C2777050379 @default.
• W2017597613 hasConceptScore W2017597613C2777457247 @default.
• W2017597613 hasConceptScore W2017597613C2777637488 @default.
• W2017597613 hasConceptScore W2017597613C2778193466 @default.
• W2017597613 hasConceptScore W2017597613C2778266534 @default.
• W2017597613 hasConceptScore W2017597613C2778897966 @default.
• W2017597613 hasConceptScore W2017597613C2779631663 @default.
• W2017597613 hasConceptScore W2017597613C4937899 @default.
• W2017597613 hasConceptScore W2017597613C501593827 @default.
• W2017597613 hasConceptScore W2017597613C523546767 @default.
• W2017597613 hasConceptScore W2017597613C54355233 @default.
• W2017597613 hasConceptScore W2017597613C71924100 @default.
• W2017597613 hasConceptScore W2017597613C86803240 @default.
• W2017597613 hasConceptScore W2017597613C89423630 @default.
• W2017597613 hasConceptScore W2017597613C94665300 @default.
• W2017597613 hasIssue "2" @default.
• W2017597613 hasLocation W20175976131 @default.
• W2017597613 hasLocation W20175976132 @default.
• W2017597613 hasOpenAccess W2017597613 @default.
• W2017597613 hasPrimaryLocation W20175976131 @default.
• W2017597613 hasRelatedWork W1997508973 @default.
• W2017597613 hasRelatedWork W2017597613 @default.
• W2017597613 hasRelatedWork W2031926041 @default.
• W2017597613 hasRelatedWork W2067876411 @default.
• W2017597613 hasRelatedWork W2137358274 @default.
• W2017597613 hasRelatedWork W2376624934 @default.
• W2017597613 hasRelatedWork W2390815598 @default.
• W2017597613 hasRelatedWork W2483700881 @default.
• W2017597613 hasRelatedWork W2515689797 @default.
• W2017597613 hasRelatedWork W2773317771 @default.
• W2017597613 hasVolume "37" @default.
• W2017597613 isParatext "false" @default.
• W2017597613 isRetracted "false" @default.
• W2017597613 magId "2017597613" @default.
• W2017597613 workType "article" @default.